The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …

Background Patients recently hospitalized for heart failure (HF) are at high risk for
rehospitalization and death. Objectives The purpose of this study was to investigate clinical …

The American Heart Association requests that this document be cited as follows:
Heidenreich PA, Fonarow GC, Breathett K, Jurgens CY, Pisani BA, Pozehl BJ, Spertus JA …

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to
reduce the risk of cardiovascular death or heart failure hospitalization and improve …

Abstract Aims The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with
sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly …

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked
increases in death and rehospitalization rates, which then decline exponentially though they …

Background Beta-blockers, angiotensin receptor-neprilysin inhibitor (ARNI),
mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors …